Literature DB >> 22761428

The transcription factor SPDEF suppresses prostate tumor metastasis.

Joshua J Steffan1, Sweaty Koul, Randall B Meacham, Hari K Koul.   

Abstract

Emerging evidence suggests that the SAM pointed domain containing ETS transcription factor (SPDEF) plays a significant role in tumorigenesis in prostate, breast, colon, and ovarian cancer. However, there are no in vivo studies with respect to the role of SPDEF in tumor metastasis. The present study examined the effects of SPDEF on tumor cell metastasis using prostate tumor cells as a model. Utilizing two experimental metastasis models, we demonstrate that SPDEF inhibits cell migration and invasion in vitro and acts a tumor metastasis suppressor in vivo. Using stable expression of SPDEF in PC3-Luc cells and shRNA-mediated knockdown of SPDEF in LNCaP-Luc cells, we demonstrate for the first time that SPDEF diminished the ability of disseminated tumors cells to survive at secondary sites and establish micrometastases. These effects on tumor metastasis were not a result of the effect of SPDEF on cell growth as SPDEF expression had no effect on cell growth in vitro or subcutaneous tumor xenograft-growth in vivo. Transcriptional analysis of several genes associated with tumor metastasis, invasion, and the epithelial-mesenchymal transition demonstrated that SPDEF expression selectively down-regulated MMP9 and MMP13 in prostate cancer cells. Further analysis indicated that forced MMP9 or MMP13 expression rescued the invasive phenotype in SPDEF expressing PC3 cells in vitro, suggesting that the effects of SPDEF on tumor invasion are mediated, in part, through the suppression of MMP9 and MMP13 expression. These results demonstrate for the first time, in any system, that SPDEF functions as a tumor metastasis suppressor in vivo.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22761428      PMCID: PMC3436170          DOI: 10.1074/jbc.M112.379396

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Na+/H+ exchangers and RhoA regulate acidic extracellular pH-induced lysosome trafficking in prostate cancer cells.

Authors:  Joshua J Steffan; Jared L Snider; Omar Skalli; Tomas Welbourne; James A Cardelli
Journal:  Traffic       Date:  2009-06       Impact factor: 6.215

2.  Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma.

Authors:  G Sehgal; J Hua; E J Bernhard; I Sehgal; T C Thompson; R J Muschel
Journal:  Am J Pathol       Date:  1998-02       Impact factor: 4.307

Review 3.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

4.  Novel role for PDEF in epithelial cell migration and invasion.

Authors:  Ruwanthi N Gunawardane; Dennis C Sgroi; Carolyn N Wrobel; Eugene Koh; George Q Daley; Joan S Brugge
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

5.  Transcriptional regulation of p21/CIP1 cell cycle inhibitor by PDEF controls cell proliferation and mammary tumor progression.

Authors:  Jeremy S Schaefer; Yamini Sabherwal; Heidi Y Shi; Venkataraman Sriraman; JoAnne Richards; Alex Minella; David P Turner; Dennis K Watson; Ming Zhang
Journal:  J Biol Chem       Date:  2010-02-05       Impact factor: 5.157

6.  MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients.

Authors:  Riyad Bendardaf; Abdelbaset Buhmeida; Marja Hilska; Matti Laato; Stina Syrjänen; Kari Syrjänen; Yrjö Collan; Seppo Pyrhönen
Journal:  Cancer Invest       Date:  2010-01       Impact factor: 2.176

7.  Prognostic value of tumor-related molecular expression in gastric carcinoma.

Authors:  Zhong-Sheng Zhao; Yuan-Yu Wang; Zai-Yuan Ye; Hou-Quan Tao
Journal:  Pathol Oncol Res       Date:  2009-03-18       Impact factor: 3.201

8.  Increased expression of MMP9 is correlated with poor prognosis of nasopharyngeal carcinoma.

Authors:  Zhen Liu; Lixia Li; Zhixiong Yang; Weiren Luo; Xin Li; Huiling Yang; Kaitai Yao; Bin Wu; Weiyi Fang
Journal:  BMC Cancer       Date:  2010-06-09       Impact factor: 4.430

9.  Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression.

Authors:  Giancarlo Castellano; Grazia Malaponte; Maria C Mazzarino; Mariangela Figini; Francesco Marchese; Pietro Gangemi; Salvatore Travali; Franca Stivala; Silvana Canevari; Massimo Libra
Journal:  Clin Cancer Res       Date:  2008-11-15       Impact factor: 12.531

Review 10.  Dissemination and growth of cancer cells in metastatic sites.

Authors:  Ann F Chambers; Alan C Groom; Ian C MacDonald
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

View more
  21 in total

1.  SPDEF: a molecular switch for E-cadherin expression that promotes prostate cancer metastasis.

Authors:  Mary Osisami; Evan T Keller
Journal:  Asian J Androl       Date:  2013-05-27       Impact factor: 3.285

2.  A tight junction between E-Cadherin and the prostate tumor suppressor SPDEF.

Authors:  Valeria Coppola; Désirée Bonci
Journal:  Asian J Androl       Date:  2013-05-27       Impact factor: 3.285

3.  Impact of Therapy on Genomics and Transcriptomics in High-Risk Prostate Cancer Treated with Neoadjuvant Docetaxel and Androgen Deprivation Therapy.

Authors:  Himisha Beltran; Alexander W Wyatt; Edmund C Chedgy; Adam Donoghue; Matti Annala; Evan W Warner; Kevin Beja; Michael Sigouros; Fan Mo; Ladan Fazli; Colin C Collins; James Eastham; Michael Morris; Mary-Ellen Taplin; Andrea Sboner; Susan Halabi; Martin E Gleave
Journal:  Clin Cancer Res       Date:  2017-08-25       Impact factor: 12.531

4.  Relative mRNA expression of prostate-derived E-twenty-six factor and E-twenty-six variant 4 transcription factors, and of uridine phosphorylase-1 and thymidine phosphorylase enzymes, in benign and malignant prostatic tissue.

Authors:  Luciane Rostirola Cavazzola; Gustavo Franco Carvalhal; Candida Deves; Daiana Renck; Ricardo Almeida; DIóGENES Santiago Santos
Journal:  Oncol Lett       Date:  2015-04-01       Impact factor: 2.967

5.  Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL)-Troglitazone-induced Apoptosis in Prostate Cancer Cells Involve AMP-activated Protein Kinase.

Authors:  Sreevidya Santha; Navin Viswakarma; Subhasis Das; Ajay Rana; Basabi Rana
Journal:  J Biol Chem       Date:  2015-07-21       Impact factor: 5.157

6.  The transcription factor sterile alpha motif (SAM) pointed domain-containing ETS transcription factor (SPDEF) is required for E-cadherin expression in prostate cancer cells.

Authors:  Mintu Pal; Sweaty Koul; Hari K Koul
Journal:  J Biol Chem       Date:  2013-02-28       Impact factor: 5.157

7.  Expression array analysis of the hepatocyte growth factor invasive program.

Authors:  Fabiola Cecchi; Chih-Jian Lih; Young H Lee; William Walsh; Daniel C Rabe; Paul M Williams; Donald P Bottaro
Journal:  Clin Exp Metastasis       Date:  2015-08-01       Impact factor: 5.150

8.  Oncogenic H-ras reprograms Madin-Darby canine kidney (MDCK) cell-derived exosomal proteins following epithelial-mesenchymal transition.

Authors:  Bow J Tauro; Rommel A Mathias; David W Greening; Shashi K Gopal; Hong Ji; Eugene A Kapp; Bradley M Coleman; Andrew F Hill; Ulrike Kusebauch; Janice L Hallows; David Shteynberg; Robert L Moritz; Hong-Jian Zhu; Richard J Simpson
Journal:  Mol Cell Proteomics       Date:  2013-05-03       Impact factor: 5.911

9.  High SPDEF may identify patients who will have a prolonged response to androgen deprivation therapy.

Authors:  Andrew C Haller; Wei Tan; Rochelle Payne-Ondracek; Willie Underwood; Lili Tian; Carl Morrison; Fengzhi Li
Journal:  Prostate       Date:  2013-12-27       Impact factor: 4.104

10.  Master regulators of FGFR2 signalling and breast cancer risk.

Authors:  Michael N C Fletcher; Mauro A A Castro; Xin Wang; Ines de Santiago; Martin O'Reilly; Suet-Feung Chin; Oscar M Rueda; Carlos Caldas; Bruce A J Ponder; Florian Markowetz; Kerstin B Meyer
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.